Lyell Immunopharma Inc (LYEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -204,472 | -129,377 | N/A | N/A |
| Depreciation Amortization | 4,833 | -262 | N/A | N/A |
| Accounts payable and accrued liabilities | -278 | 1,709 | N/A | N/A |
| Other Working Capital | -336 | 110,808 | N/A | N/A |
| Other Operating Activity | 39,379 | 56,596 | 0 | 0 |
| Operating Cash Flow | $-160,874 | $39,474 | $N/A | $N/A |
| Cash Flows From Investing Activities | ||||
| Change In Deposits | -222,035 | -406,386 | N/A | N/A |
| PPE Investments | -51,481 | -16,047 | N/A | N/A |
| Investing Cash Flow | $-273,516 | $-422,433 | $N/A | $N/A |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 373 | N/A | N/A | N/A |
| Common Stock Repurchased | -11,806 | -185 | N/A | N/A |
| Other Financing Activity | 488,223 | 351,341 | 0 | 0 |
| Financing Cash Flow | $476,790 | $351,156 | $N/A | $N/A |
| Beginning Cash Position | 98,472 | 130,275 | N/A | N/A |
| End Cash Position | 140,872 | 98,472 | N/A | N/A |
| Net Cash Flow | $42,400 | $-31,803 | $N/A | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | -160,874 | 39,474 | N/A | N/A |
| Capital Expenditure | -51,481 | -16,047 | N/A | N/A |
| Free Cash Flow | -212,355 | 23,427 | 0 | 0 |